Jan192021UncategorizedCategory: UncategorizedBy Charlotte Maddalena19 January 2021 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Six new projects supported by our Foundation and our Endowment FundNextNext post:Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of HypoparathyroidismRelated PostsORPHELIA Pharma will participate to the ANR 20239 May 2023ORPHELIA Pharma will participate to the SIOPe 20232 May 2023ORPHELIA Pharma Selects Tanner Pharma to Initiate Named Patient Program for KIMOZO®18 April 2023Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 14-19 in Orlando, Florida17 April 2023ORPHELIA Pharma announces completion of patient recruitment for the TEMOkids clinical trial2 March 2023OREGA Biotech enters into a License Agreement with Genmab6 December 2022
Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 14-19 in Orlando, Florida17 April 2023
ORPHELIA Pharma announces completion of patient recruitment for the TEMOkids clinical trial2 March 2023
